Nanohale AG (ETR:FYB) | WebDisclosure

Basculer en Français

9480	Companies
185554	Keywords
117943	Articles
99386	Press releases

Home
Companies
Nanohale AG

PRESS RELEASE

published on 02/24/2025 at 11:26, 9 months 9 days ago

Original-Research: Formycon AG (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research updates its research on Formycon AG, maintaining a Buy recommendation with a decreased target price from EUR 82 to EUR 46 due to higher price pressure and reduced investments in biosimilar portfolio

First Berlin Equity Research Buy Recommendation Research Update Formycon AG Biosimilar Portfolio
BRIEF

published on 02/20/2025 at 06:35, 9 months 13 days ago

Formycon dévoile les données cliniques du biosimilaire d'ustekinumab FYB202 au congrès de l'ECCO

Formycon AG FYB202 Biosimilaire Approbation Réglementaire Données Cliniques
BRIEF

published on 02/20/2025 at 06:35, 9 months 13 days ago

Formycon Unveils Clinical Data for Ustekinumab Biosimilar FYB202 at ECCO Congress

Formycon AG Regulatory Approval Clinical Data Biosimilar FYB202
PRESS RELEASE

published on 02/20/2025 at 06:30, 9 months 13 days ago

Formycon presents clinical data on ustekinumab biosimilar FYB202 at the ECCO Congress in Berlin
Formycon presents clinical data on ustekinumab biosimilar FYB202 at ECCO Congress, demonstrating comparability with Stelara. FYB202 approved in multiple regions

Clinical Data ECCO Congress Biosimilar Formycon Ustekinumab
BRIEF

published on 02/17/2025 at 09:32, 9 months 16 days ago

Formycon AG Updates on Biosimilar Projects and Strategic Adjustments

FDA Approval Biosimilars Financial Adjustments Commercial Strategy Price Discounts
BRIEF

published on 02/17/2025 at 09:32, 9 months 16 days ago

Formycon AG fait le point sur ses projets biosimilaires et ses ajustements stratégiques

Stratégie Commerciale Approbation De La FDA Biosimilaires Ajustements Financiers Réductions De Prix
PRESS RELEASE

published on 02/17/2025 at 09:27, 9 months 16 days ago

Formycon AG informs about recent developments in various biosimilar projects and invites to conference call
Formycon AG provides updates on various biosimilar projects, including terminating phase III trial for FYB206. Conference call on Feb 17, 2025, to discuss recent developments

FDA Conference Call Formycon AG FYB206 Biosimilar Projects
BRIEF

published on 02/17/2025 at 08:10, 9 months 16 days ago

Formycon Updates on Phase III Trial and Valuation Adjustments

Formycon AG FDA Feedback Phase III Trial Commercialization Strategy Biosimilar Valuation
BRIEF

published on 02/17/2025 at 08:10, 9 months 16 days ago

Formycon fait le point sur l'essai de phase III et les ajustements de valorisation

Formycon AG Stratégie De Commercialisation Essai De Phase III Commentaires De La FDA Évaluation Des Biosimilaires
PRESS RELEASE

published on 02/17/2025 at 08:05, 9 months 16 days ago

EQS-Adhoc: Formycon announces decision on Phase III trial with FYB206 and provides update on potential need to adjust the valuation of FYB202 and FYB201
Formycon terminates Phase III trial for FYB206 after FDA feedback, anticipates valuation adjustments for FYB202 & FYB201 due to price discounts

FDA Feedback Valuation Adjustments Formycon FYB206 Price Discounts

Accesswire

Published on 12/05/2025 at 21:20, 11 minutes ago

Medicus Pharma Ltd. Enters Into $5.1 Million Warrant Inducement
Published on 12/05/2025 at 21:00, 31 minutes ago

The Repricing Event: Why Multiple Global Industries Are Suddenly Moving Toward SMX
Published on 12/05/2025 at 20:25, 1 hour 6 minutes ago

The Feedback Loop: Why SMX's Adoption in One Industry Accelerates Interest in All the Others
Published on 12/05/2025 at 20:15, 1 hour 16 minutes ago

When Proof Becomes Infrastructure, Markets Rewrite the Story (NASDAQ: SMX)
Published on 12/05/2025 at 19:50, 1 hour 41 minutes ago

Gold, Rare Earth Minerals, Digital Assets: The Market Just Realized SMX Sits in All Three

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 18:58, 2 hours 33 minutes ago

EQS-Adhoc: HORNBACH Holding AG & Co. KGaA: Reduced earnings in Q3 2025/26 – Guidance for adjusted EBIT at previous year’s level still valid
Published on 12/05/2025 at 18:26, 3 hours 5 minutes ago

POS-Transaction in Own Shares
Published on 12/05/2025 at 18:15, 3 hours 16 minutes ago

Completion of merger to form Helvetia Baloise Holding Ltd
Published on 12/05/2025 at 17:51, 3 hours 39 minutes ago

Issue of Equity
Published on 12/05/2025 at 17:46, 3 hours 45 minutes ago

Booster Precision Components Holding GmbH announces the successful completion of its Written Procedure to amend and waive certain terms under the terms and conditions of the Bonds

Les Echos

Published on 12/05/2025 at 17:18, 4 hours 13 minutes ago

La vidéo de la réunion de présentation des résultats 2024-2025 du 5 décembre 2025 est disponible
Published on 12/05/2025 at 17:18, 4 hours 13 minutes ago

The video of the 2024-2025 results presentation meeting on December 5, 2025, is available
Published on 12/05/2025 at 15:10, 6 hours 20 minutes ago

Mersen: Number of shares and voting rights as of November 30, 2025
Published on 12/05/2025 at 15:10, 6 hours 20 minutes ago

Mersen : nombre d'actions et de droits de vote au 30 novembre 2025
Published on 12/05/2025 at 13:58, 7 hours 33 minutes ago

RELATIF A LA MISE A DISPOSITION DU PUBLIC DE LA NOTE D'INFORMATION ET DES INFORMATIONS RELATIVES AUX CARACTERISTIQUES, NOTAMMENT JURIDIQUES, FINANCIERES ET COMPTABLES DE LEGRAND FRANCE

View all LES ECHOS COMFI WIRE